May 13th 2024
In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Findings With the Antibody Drug Conjugate D3-GPC2-PBD
April 18th 2018Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.
Watch
The Significance of Brain Metastases in Non-Small Cell Lung Cancer
March 21st 2018Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer.
Watch
Earlier Pseudoprogression Seen in Patients With Oligodendroglioma Treated With Proton Therapy
March 21st 2018Patients with oligodendroglioma developed pseudoprogression earlier after treatment with proton therapy compared with after photon therapy, according to the results of a retrospective study comparing the rates of pseudoprogression that occurred in patients with anaplastic gliomas following treatment with different radiation therapy modalities.
Read More
TTFields with Temozolomide Recommended by NCCN for Newly Diagnosed GBM
March 21st 2018The combination of TTFields and temozolomide has been added by the NCCN to its guidelines for Category 1 treatment for patients with newly diagnosed glioblastoma, following maximal safe resection and completion of radiation therapy.
Read More
Cabozantinib Active in Relapsed/Refractory Glioblastoma
February 21st 2018In results of a phase II study, cabozantinib (Cabometyx) showed signs of activity in patients with progressive glioblastoma who were naïve to antiangiogenic therapy, despite the predefined statistical target for success not being met.
Read More